|
|
News Breaks | | | | February 19, 2013 | | 07:34 EDT |  | ACRX | AcelRx says Phase 3 trials continue to progress
AcelRx Pharmaceuticals announced continuing progress on its two remaining Phase 3 trials of the Sufentanil NanoTab PCA System being studied in post-operative pain. The first of those studies in patients after major abdominal surgery completed the last patient earlier this quarter, and is expected to provide data later this quarter. The second study, in patients after major orthopedic surgery, continues to enroll patients, with the last patient expected to enroll around the end of the first quarter of 2013, and data expected in the second quarter. A New Drug Application submission for the NanoTab System remains on track for the third quarter of 2013. In addition, a Phase 2 clinical trial with ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, has completed dosing and results from this study are expected to be available in the second quarter of 2013, the company said. | |
|
News For ACRX From The Last 14 Days Check below for free stories on ACRX the last two weeks. |
|
|
| May 21, 2013 | | 09:29 EDT |  | ACRX | AcelRx rises after positive Phase 3 of of Sufentanil PCA system
 Subscribe for More Information | | | 08:05 EDT |  | ACRX | AcelRx to host a webcast
Subscribe for More Information | | | 07:36 EDT | | ACRX | AcelRx announces positive results from Phase 3 study of Sufentanil PCA system
Subscribe for More Information | | | May 15, 2013 | | 11:01 EDT | | ACRX | AcelRx management to meet with Guggenheim
Subscribe for More Information | | | May 8, 2013 | | 16:34 EDT |  | ACRX | AcelRx reports Q1 EPS (34c), consensus (27c)
Subscribe for More Information | |
|
|
|
|
|
|
